

Remarks / Arguments

As a result of this amendment, claims 1-5, 11, and 15-21 are pending in the application. Claims 6-10 are cancelled in this amendment, and claims 12-14 were cancelled previously. Claims 1-5, 15-16, and 19 have been amended. No new matter has been added.

The claims have been amended to delete non-elected subject matter.

Claim 5 has been amended to place it in the more usual US form.

Previously withdrawn claims 6-10, drawn to intermediates, have been cancelled.

Claims 19-21 were rejected under §112, first paragraph, as not being enabled with respect to prophylaxis of the recited conditions. The language “or prophylaxis” has now been deleted from claim 19, as suggested by the examiner.

Claims 1-5, 11, and 15-18 were provisionally rejected on grounds of obviousness-type double patenting in view of copending application Serial No. 09/980242. A terminal disclaimer is being submitted with this response to overcome this rejection.

Patent Office personnel are informed that because a strike-through associated with punctuation marks such as a comma, semicolon, colon, or period is difficult to see, in making amendments to certain of the claims, some language is deleted and re-inserted in order to clarify the amendments with respect to affected punctuation marks. Any such deletion/re-insertion does not affect the meaning or scope of the claim in which it occurs. Similarly, because a strike-through of a single letter or a few letters of a word is difficult to see, when a word is to be modified, the entire word is deleted and the modified form of the word is re-introduced.

In view of the above amendments and explanations, this application is deemed to be in condition for allowance, and allowance is accordingly requested.

Respectfully submitted,

Reg. No. 31018

Phone: (203) 812-2712

Date: 21 July 2003

William F. Gray

William F. Gray

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175